• Cromore Road, Coleraine Campus

    BT52 1SA Coleraine

    United Kingdom

  • 822 Citations
  • 12 h-Index
If you made any changes in Pure these will be visible here soon.

Personal profile


Dr Murtaza Tambuwala is a Pharmacist and has completed his doctoral research at School of Medicine and Medical Sciences, University College Dublin in 2011 under the auspices of Prof. Cormac Taylor and Dr Ivan Coulter (CEO of Sublimity Therapeutics) which was funded by Enterprise Partnership Doctoral Research Award from Irish Research Council. He has undertaking postdoctoral training at Trinity Translational Medicine Institute, Trinity College Dublin under the tutelage of Prof. Padraic Fallon with funding post-doctoral research award obtained from Irish Research Council.

Dr Tambuwala joined Ulster University as a Lecturer in 2013 and established his independent research lab. The over-arching aims of his research lab are to understand the mechanisms by which hypoxia regulates transcriptional events in inflammation and development of cancer. In particular, he is interested in the regulation of global gene expression in response to hypoxic environment of inflamed tissue/tumour, and the modification of transcriptional regulators which underlies the induction of inflammation, development and progression of cancer. His research lab is focussed on translating this understanding of hypoxia-sensitive pathways to developing new therapeutics in chronic inflammatory disease, intestinal fibrosis and colon and breast cancers.

To achieve the overall objectives of new and better medicines his lab is working on:

1. Developing novel drug delivery systems to target inflamed tissue and cancer tumours.

2. Investigate the biomolecular mechanism of natural compounds in inflammation and cancer.

3. Use 3D printing technologies to develop personalised oral drug delivery system (Tablets) for IBD patients.

4. Application of 3D bioprinting to develop novel models for IBD, colon and breast cancer to reduce the use of animals in research.

Dr Tambuwala initiated and directs the MSc in Pharmaceutical Sciences via Distant learning (Online) at Ulster University and is an active contributor in the delivery and development of MPharm programme at the School of Pharmacy and Pharmaceutical Sciences.

Dr Tambuwala also serves as a reviewer for UK research councils and several esteemed journals in the field of inflammatory bowel diseases and drug delivery.

Education/Academic qualification

PhD, University College Dublin


Master, Trinity College Dublin

External positions

Editorial board Member

Editorial Board Member

Thesis examiner


  • RB Pathology
  • RM Therapeutics. Pharmacology
  • RS Pharmacy and materia medica

Fingerprint Dive into the research topics where Murtaza Tambuwala is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles
Colitis Medicine & Life Sciences
Mixed Function Oxygenases Medicine & Life Sciences
Nanoparticles Medicine & Life Sciences
Inflammatory Bowel Diseases Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Prolyl Hydroxylases Medicine & Life Sciences
Inflammation Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2009 2019

30 Citations (Scopus)

Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis.

Tambuwala, M. M., Manresa, M. C., Cummins, E. P., Aversa, V., Coulter, I. S. & Taylor, C., 16 Sep 2015, In : Journal of Controlled Release. 217, p. 221-227

Research output: Contribution to journalArticle

Open Access
Mixed Function Oxygenases
Gastric Acid
28 Citations (Scopus)

Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation

Murphy, A., Thomas, A., Crinion, S., Kent, B., Tambuwala, M., Fabre, A., PEPIN, J-L., Roche, H., ARNAUD, C. & Ryan, S., 19 Apr 2017, In : European Respiratory Journal. 49

Research output: Contribution to journalArticle

Open Access
Obstructive Sleep Apnea
Insulin Resistance
Adipose Tissue
22 Citations (Scopus)

Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon

Ward, J. B. J., Lajczak, N. K., Kelly, O. B., O'Dwyer, A. M., Giddam, A. K., Ní Gabhainn, J. N., Franco, P., Tambuwala, M. M., Jefferies, C. A., Keely, S., Roda, A. & Keely, S. J., 30 Mar 2017, In : AJP - Gastrointestinal and Liver Physiology. 312, 6, p. G550-G558

Research output: Contribution to journalArticle

Open Access
Lithocholic Acid
Ursodeoxycholic Acid
Anti-Inflammatory Agents
Bile Acids and Salts
12 Citations (Scopus)

REST is a hypoxia-responsive transcriptional repressor

Cavadas, M. A. S., Mesnieres, M., Crifo, B., Manresa, M. C., Selfridge, A. C., Keogh, C. E., Fabian, Z., Scholz, C. C., Nolan, K. A., Rocha, L. M. A., Tambuwala, M., Brown, S., Wdowicz, A., Corbett, D., Murphy, K. J., Godson, C., Cummins, E. P., Taylor, C. T. & Cheong, A., 17 Aug 2016, In : Scientific Reports. 6, 31355, p. 1-22

Research output: Contribution to journalArticle

Open Access
Transcriptional Silencer Elements
Transcription Factors
Gene Expression
105 Citations (Scopus)

Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function

Tambuwala, M., Cummins, E. P., Lenihan, C. R., Kiss, J., Stauch, M., Scholz, C. C., Fraisl, P., Lasitschka, F., Mollenhauer, M., Saunders, S. P., Maxwell, P. H., Carmeliet, P., Fallon, P. G., Schneider, M. & Taylor, C. T., 3 Dec 2010, 139, 6, p. 2093

Research output: Contribution to journalArticle

Open Access